Exposure-adjusted safety analyses of the VISION phase 3 trial of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Kim N. Chi, Nabil Adra, Rohan Garje, Jeff M. Michalski, Jules Lavalaye, Mette Moe Kempel, Marcia Brackman, Kevin Perraud, Geoffrey Holder, Andrew J. Armstrong

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Fingerprint

Dive into the research topics of 'Exposure-adjusted safety analyses of the VISION phase 3 trial of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science